A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia

Ian D. Maidment, C. Fox, Malaz Boustani

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To review the literature relating to the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia (PDD). Method: MEDLINE (1966 - December 2004), PsychINFO (1972 - December 2004), EMBASE (1980 - December 2004), CINHAL (1982 - December 2004), and the Cochrane Collaboration were searched in December 2004. Results: Three controlled trials and seven open studies were identified. Efficacy was assessed in three key domains: cognitive, neuropsychiatric and parkinsonian symptoms. Conclusion: Cholinesterase inhibitors have a moderate effect against cognitive symptoms. There is no clear evidence of a noticeable clinical effect against neuropsychiatric symptoms. Tolerability including exacerbation of motor symptoms - in particular tremor - may limit the utility of cholinesterase inhibitors.

Original languageEnglish (US)
Pages (from-to)403-409
Number of pages7
JournalActa Psychiatrica Scandinavica
Volume111
Issue number6
DOIs
StatePublished - Jun 2005

Fingerprint

Cholinesterase Inhibitors
Parkinson Disease
Dementia
Neurobehavioral Manifestations
Tremor
MEDLINE

Keywords

  • Cholinesterase inhibitors
  • Parkinson's disease
  • Parkinson's disease dementia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia. / Maidment, Ian D.; Fox, C.; Boustani, Malaz.

In: Acta Psychiatrica Scandinavica, Vol. 111, No. 6, 06.2005, p. 403-409.

Research output: Contribution to journalArticle

@article{258d4b0a03084d5fa9145c1f0b1278ea,
title = "A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia",
abstract = "Objective: To review the literature relating to the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia (PDD). Method: MEDLINE (1966 - December 2004), PsychINFO (1972 - December 2004), EMBASE (1980 - December 2004), CINHAL (1982 - December 2004), and the Cochrane Collaboration were searched in December 2004. Results: Three controlled trials and seven open studies were identified. Efficacy was assessed in three key domains: cognitive, neuropsychiatric and parkinsonian symptoms. Conclusion: Cholinesterase inhibitors have a moderate effect against cognitive symptoms. There is no clear evidence of a noticeable clinical effect against neuropsychiatric symptoms. Tolerability including exacerbation of motor symptoms - in particular tremor - may limit the utility of cholinesterase inhibitors.",
keywords = "Cholinesterase inhibitors, Parkinson's disease, Parkinson's disease dementia",
author = "Maidment, {Ian D.} and C. Fox and Malaz Boustani",
year = "2005",
month = "6",
doi = "10.1111/j.1600-0447.2005.00516.x",
language = "English (US)",
volume = "111",
pages = "403--409",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia

AU - Maidment, Ian D.

AU - Fox, C.

AU - Boustani, Malaz

PY - 2005/6

Y1 - 2005/6

N2 - Objective: To review the literature relating to the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia (PDD). Method: MEDLINE (1966 - December 2004), PsychINFO (1972 - December 2004), EMBASE (1980 - December 2004), CINHAL (1982 - December 2004), and the Cochrane Collaboration were searched in December 2004. Results: Three controlled trials and seven open studies were identified. Efficacy was assessed in three key domains: cognitive, neuropsychiatric and parkinsonian symptoms. Conclusion: Cholinesterase inhibitors have a moderate effect against cognitive symptoms. There is no clear evidence of a noticeable clinical effect against neuropsychiatric symptoms. Tolerability including exacerbation of motor symptoms - in particular tremor - may limit the utility of cholinesterase inhibitors.

AB - Objective: To review the literature relating to the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia (PDD). Method: MEDLINE (1966 - December 2004), PsychINFO (1972 - December 2004), EMBASE (1980 - December 2004), CINHAL (1982 - December 2004), and the Cochrane Collaboration were searched in December 2004. Results: Three controlled trials and seven open studies were identified. Efficacy was assessed in three key domains: cognitive, neuropsychiatric and parkinsonian symptoms. Conclusion: Cholinesterase inhibitors have a moderate effect against cognitive symptoms. There is no clear evidence of a noticeable clinical effect against neuropsychiatric symptoms. Tolerability including exacerbation of motor symptoms - in particular tremor - may limit the utility of cholinesterase inhibitors.

KW - Cholinesterase inhibitors

KW - Parkinson's disease

KW - Parkinson's disease dementia

UR - http://www.scopus.com/inward/record.url?scp=20144369487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144369487&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0447.2005.00516.x

DO - 10.1111/j.1600-0447.2005.00516.x

M3 - Article

C2 - 15877706

AN - SCOPUS:20144369487

VL - 111

SP - 403

EP - 409

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

SN - 0001-690X

IS - 6

ER -